SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:prod.swepub.kib.ki.se:152432881"
 

Search: onr:"swepub:oai:prod.swepub.kib.ki.se:152432881" > Rituximab versus az...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Smith, RM (author)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • 2023-03-23
  • BMJ,2023

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:152432881
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:152432881URI
  • https://doi.org/10.1136/ard-2022-223559DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab.MethodsRITAZAREM was an international randomised controlled, open-label, superiority trial that recruited 188 patients at the time of an AAV relapse from 29 centres in seven countries between April 2013 and November 2016. All patients received rituximab and glucocorticoids to reinduce remission. Patients achieving remission by 4 months were randomised to receive rituximab intravenously (1000 mg every 4 months, through month 20) (85 patients) or azathioprine (2 mg/kg/day, tapered after month 24) (85 patients) and followed for a minimum of 36 months. The primary outcome was time to disease relapse (either major or minor relapse).ResultsRituximab was superior to azathioprine in preventing relapse: HR 0.41; 95% CI 0.27 to 0.61, p<0.001. 19/85 (22%) patients in the rituximab group and 31/85 (36%) in the azathioprine group experienced at least one serious adverse event during the treatment period. There were no differences in rates of hypogammaglobulinaemia or infection between groups.ConclusionsFollowing induction of remission with rituximab, fixed-interval, repeat-dose rituximab was superior to azathioprine for preventing disease relapse in patients with AAV with a prior history of relapse.Trial registration numberNCT01697267; ClinicalTrials.gov identifier

Added entries (persons, corporate bodies, meetings, titles ...)

  • Jones, RB (author)
  • Specks, U (author)
  • Bond, S (author)
  • Nodale, M (author)
  • Al-jayyousi, R (author)
  • Andrews, J (author)
  • Bruchfeld, AKarolinska Institutet (author)
  • Camilleri, B (author)
  • Carette, S (author)
  • Cheung, CK (author)
  • Derebail, V (author)
  • Doulton, T (author)
  • Ferraro, A (author)
  • Forbess, L (author)
  • Fujimoto, S (author)
  • Furuta, S (author)
  • Gewurz-Singer, O (author)
  • Harper, L (author)
  • Ito-Ihara, T (author)
  • Khalidi, N (author)
  • Klocke, R (author)
  • Koening, C (author)
  • Komagata, Y (author)
  • Langford, C (author)
  • Lanyon, P (author)
  • Luqmani, R (author)
  • McAlear, C (author)
  • Moreland, LW (author)
  • Mynard, K (author)
  • Nachman, P (author)
  • Pagnoux, C (author)
  • Peh, CA (author)
  • Pusey, C (author)
  • Ranganathan, D (author)
  • Rhee, RL (author)
  • Spiera, R (author)
  • Sreih, AG (author)
  • Tesar, V (author)
  • Walters, G (author)
  • Wroe, C (author)
  • Jayne, D (author)
  • Merkel, PA (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Annals of the rheumatic diseases: BMJ82:7, s. 937-9441468-20600003-4967

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view